Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.
Jacob Cohen, Peter Parbo, Per Trads Ørskov, Dirk Wildgruber, Benjamin Kreifelts, Ulrich Kirk, Oke Gerke, Martin Korsbak Madsen, Mikael Palner
PsyArXiv May 14, 2026 preprint DOI: 10.31234/osf.io/3b9fx_v1
Summary
AI-generated from the abstractA double-blind randomized controlled trial will test whether low doses of psilocybin, given alongside virtual reality exposure therapy, can reduce symptoms of social anxiety disorder. The protocol describes the planned methods but does not yet report results.
Study at a glance
| Characteristics | Randomized controlled trial Double-blind |
|---|---|
| Population | People with social anxiety disorder |
| Key finding | The protocol outlines a planned trial to evaluate psilocybin as an adjunct to virtual reality exposure therapy for social anxiety disorder; no findings are reported. |
Abstract
Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.